Policy & Regulation
Antengene reports first patient dosed in Phase I study of ATG-201 in B cell-mediated autoimmune diseases
6 November 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996) announced on Thursday that the first patient has been dosed in China in the Phase I ATTRACT study evaluatin...
Akeso publishes ivonescimab Phase II study results in Nature Medicine
6 November 2026 - Chinese pharmaceutical company Akeso Inc (HKEX:9926) announced on Thursday that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivo...
Chinese regulator accepts Lynk Pharmaceuticals' New Drug Application for zemprocitinib in RA treatment
6 November 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, announced on Thursday that the New Drug Application (NDA) for i...
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
5 November 2026 - French biotech company Transgene (Euronext Paris:TNG) and the University of Copenhagen have dosed the first patient in the Phase 1 OV-PRIME-R trial evaluating BT-001 in patients with...
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
5 November 2026 - SK Biopharmaceuticals Co Ltd, a South Korea-based pharmaceutical company, announced on Wednesday that it has submitted a supplemental New Drug Application (sNDA) to the US Food and D...
Circular Genomics and PharmatrophiX collaborate on advancing circRNA biomarkers in neurodegenerative drug development
5 November 2026 - Circular Genomics Inc, a precision neurology company developing circular RNA (circRNA)-based biomarkers, and PharmatrophiX Inc, a clinical-stage biopharmaceutical company developing ...